Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD

Adults with type 2 diabetes on semaglutide injection 1 mg, whose dose was increased to 2 mg, were associated with a statistically significant 6% lower risk of major adverse cardiovascular events (MACE), compared to switching to tirzepatide (up to 15 mg)1 Retrospective real-world analysis of claims data for 636,525 adults living with type 2 diabetes compared outcomes for those escalated to semaglutide 2 mg versus switching to tirzepatide1 Results from the COMPETE SWITCH CV study provide insights into GLP-1 RA treatment adjustment in adults with type 2 diabetes PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Sept.